Mayo Clinic is renowned for its multidisciplinary approach integrating oral medicine, pharmacology, and otolaryngology to study and manage drug-related oral adverse effects including halitosis. Their extensive clinical research infrastructure supports advanced studies on medication-induced xerostomia and osteonecrosis of the jaw.

UCSF leads in oral medicine research with a focus on drug-induced oral conditions such as xerostomia and halitosis. Their pharmacology department collaborates closely with dental researchers to explore mechanisms of drug side effects and develop management protocols.

Harvard Dental Medicine is a leader in oral pathology and pharmacology research, with significant contributions to understanding drug-induced oral adverse effects including halitosis. Their collaborative research environment fosters innovation in diagnosis and treatment strategies.

King's College London has a strong reputation in oral medicine and pharmacology research, particularly in drug-induced oral diseases and halitosis. Their clinical and translational research programs address the impact of systemic medications on oral health.

UNC Adams School of Dentistry is recognized for its research in oral medicine and pharmacology, focusing on drug-induced oral conditions including halitosis and xerostomia. Their integrated clinical research programs support advances in diagnosis and treatment.